View List of publications (PDF, 194 KB)

Abstracts from recent conferences

Exploiting the unique mechanism of action of sapacitabine (CYC682) to obtain synergy with other therapeutic agents for clinical use in Acute Myeloid Leukemia. View full details ( PDF, 139 KB)

A randomized phase 2 study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. View full details (PDF, 214 KB)

A phase 2 randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. View full details (PDF, 103 KB)

Synergistic interactions between sapacitabine (CYC682), and inhibitors of either histone deacetylases or methyltransferases in Acute Myeloid Leukemia cell lines. View full details (PDF, 30 KB)

Derivatives of seliciclib with improved potency, both in vitro and in vivo as novel cyclin dependent kinase (CDK) inhibitors. View full details (PDF, 39 KB)

Targeting cyclin E-Cdk-2, Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe and apoptosis. View full details (PDF, 32 KB)

Abstract # 4552, Synergistic interactions between sapacitabine (CYC682) and inhibitors of either histone deacetylase or methyltransferase in acute myeloid leukemia cell lines. View full details (PDF, 158 KB)

Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharangeal Cancer. View full details (PDF, 359 KB)

Abstract # 0638 Impact of DNA repair proteins on cell survival in response to damage induced by the DNA self-strand-breaking nucleoside analogue CNDAC. View full details (PDF, 140 KB)

Abstract # 0651 The Basis of Cell Sensitivity to Aurora A/B Inhibitors. View full details (PDF, 175 KB)

Abstract # 0801 Optimal cancer chronotherapeutic schedules of Seliciclib revealed by a systems biology approach. View full details (PDF, 816 KB)

Abstract # 1645 Systems biology analysis of CYC116, a novel aurora kinase inhibitor. View full details (PDF, 875 KB)

Abstract # 4015 Combination studies with the oral Aurora kinase inhibitor CYC116 and chemotherapeutic agents. View full details (PDF, 295 KB)

Abstract # 5511 Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma. View full details (PDF, 673 KB)

Abstract # 5644 Anti-tumor activity of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. View full details (PDF, 222 KB)

Abstract # 5645 In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. View full details (PDF, 184 KB)

Abstract # 470 The nucleoside analogue sapacitabine (CYC682) synergises with histone deacetylase inhibitors in multiple tumour types. View full details (PDF, 1 MB)

Abstract # 3502 Understanding tha patheways involved in the repair of CNDAC induced DNA damage. View full details (PDF, 272 KB)

Abstract # 3886 Therapeutic potential of CDK inhibitors in MLL leaukemias. View full details (PDF, 396 KB)

Abstract # 4435 Discovery, biological characterization and oral antitumor activity of polo-like kinase 1 (Plk1) selective small molecule inhibitors. View full details (PDF, 599 KB)

Abstract # 4431 A novel derivatie of the Cdk inhibitor roscovtine that induces adoptosis in CLL and overcomes stromal cell-mediated protection. View full details (PDF, 1.98 MB)

Abstract # 633 Tumor cell resistance mechanisms to autora kinase inhibitors. View full details (PDF, 3.83 MB)

Abstract # 22 Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer. View full details (PDF, 4.74 MB)